CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
CalciMedica (Nasdaq: CALC), a clinical-stage biopharmaceutical company specializing in CRAC channel inhibition therapies, announced its participation in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference. CEO Rachel Leheny, Ph.D. will engage in a fireside chat on July 14, 2025, at 2:00 p.m. ET.
The presentation will be accessible through a live webcast in the "IR Events and Presentations" section of CalciMedica's investor relations website, with a replay available for 90 days following the event.
CalciMedica (Nasdaq: CALC), un'azienda biofarmaceutica in fase clinica specializzata in terapie di inibizione del canale CRAC, ha annunciato la sua partecipazione alla prossima Conferenza Virtuale Annuale sul Rene H.C. Wainwright, quarta edizione. La CEO Rachel Leheny, Ph.D., parteciperà a una conversazione informale il 14 luglio 2025, alle 14:00 ET.
La presentazione sarà disponibile tramite webcast in diretta nella sezione "IR Events and Presentations" del sito web per gli investitori di CalciMedica, con una replica accessibile per 90 giorni dopo l'evento.
CalciMedica (Nasdaq: CALC), una empresa biofarmacéutica en etapa clínica especializada en terapias de inhibición del canal CRAC, anunció su participación en la próxima Conferencia Virtual Anual del Riñón H.C. Wainwright, cuarta edición. La CEO Rachel Leheny, Ph.D. participará en una charla junto a la chimenea el 14 de julio de 2025, a las 2:00 p.m. ET.
La presentación estará disponible a través de una transmisión en vivo en la sección "IR Events and Presentations" del sitio web de relaciones con inversores de CalciMedica, con una repetición disponible durante 90 días después del evento.
CalciMedica (나스닥: CALC)는 CRAC 채널 억제 치료제를 전문으로 하는 임상 단계 바이오제약 회사로, 다가오는 H.C. Wainwright 제4회 연례 신장 가상 컨퍼런스에 참여할 것이라고 발표했습니다. CEO Rachel Leheny, Ph.D.가 2025년 7월 14일 오후 2시(동부시간)에 화상 대화에 참여합니다.
발표는 CalciMedica 투자자 관계 웹사이트의 "IR Events and Presentations" 섹션에서 라이브 웹캐스트로 시청할 수 있으며, 행사 후 90일 동안 다시보기 서비스가 제공됩니다.
CalciMedica (Nasdaq : CALC), une société biopharmaceutique en phase clinique spécialisée dans les thérapies d'inhibition des canaux CRAC, a annoncé sa participation à la prochaine conférence virtuelle annuelle sur le rein H.C. Wainwright, 4e édition. La PDG Rachel Leheny, Ph.D. participera à une discussion informelle le 14 juillet 2025 à 14h00 ET.
La présentation sera accessible via un webcast en direct dans la section « IR Events and Presentations » du site web des relations investisseurs de CalciMedica, avec une rediffusion disponible pendant 90 jours après l'événement.
CalciMedica (Nasdaq: CALC), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf CRAC-Kanal-Inhibitions-Therapien spezialisiert hat, gab seine Teilnahme an der bevorstehenden 4. jährlichen virtuellen Nierenkonferenz von H.C. Wainwright bekannt. Die CEO Rachel Leheny, Ph.D. wird am 14. Juli 2025 um 14:00 Uhr ET an einem Fireside-Chat teilnehmen.
Die Präsentation wird über einen Live-Webcast im Bereich "IR Events and Presentations" auf der Investor-Relations-Website von CalciMedica zugänglich sein, mit einer Wiedergabe, die 90 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
A live webcast of the presentation can be accessed in the "IR Events and Presentations" section of CalciMedica's IR website. A replay of the webcast will be archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and for a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE –NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). For more information, please visit www.calcimedica.com.
Contact Information
Argot Partners
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-hc-wainwright-4th-annual-kidney-virtual-conference-302499225.html
SOURCE CalciMedica, Inc.
FAQ
When is CalciMedica (CALC) presenting at the H.C. Wainwright Kidney Conference 2025?
How can investors access CalciMedica's (CALC) presentation at the H.C. Wainwright conference?
What type of therapies is CalciMedica (CALC) developing?
Who will represent CalciMedica (CALC) at the H.C. Wainwright Kidney Conference?
